메뉴 건너뛰기




Volumn 52, Issue 6, 2011, Pages 1024-1029

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

(30)  Sohn, Sang Kyun a   Oh, Suk Joong b   Kim, Byung Soo c   Ryoo, Hun Mo d   Chung, Joo Seop e   Joo, Young Don f   Bang, Soo Mee g   Jung, Chul Won b   Kim, Dong Hwan b   Yoon, Sung Soo h   Kim, Ho In h   Lee, Hong Ghi i   Won, Jong Ho j   Min, Yoo Hong k   Cheong, June Won k   Park, Joon Seong l   Eom, Ki Seong m   Hyun, Myung Soo n   Kim, Min Kyoung n   Kim, Hawk o   more..


Author keywords

Chronic myeloid leukemia; cytogenetic response; imatinib; molecular response; trough blood level

Indexed keywords

IMATINIB;

EID: 79957452443     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.563885     Document Type: Article
Times cited : (29)

References (21)
  • 3
    • 2942593704 scopus 로고    scopus 로고
    • Optimizing treatment of chronic myeloid leukemia: A rational approach
    • DOI 10.1634/theoncologist.9-3-259
    • Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9:259-270. (Pubitemid 38756875)
    • (2004) Oncologist , vol.9 , Issue.3 , pp. 259-270
    • Stone, R.M.1
  • 4
    • 58549109605 scopus 로고    scopus 로고
    • Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    • Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009;33:506-508.
    • (2009) Leuk Res , vol.33 , pp. 506-508
    • Kiguchi, T.1    Tauchi, T.2    Ito, Y.3    Miyazawa, K.4    Kimura, Y.5    Ohyashiki, K.6
  • 5
    • 0037438640 scopus 로고    scopus 로고
    • BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
    • DOI 10.1182/blood.V101.2.690
    • Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698. (Pubitemid 36077594)
    • (2003) Blood , vol.101 , Issue.2 , pp. 690-698
    • Donato, N.J.1    Wu, J.Y.2    Stapley, J.3    Gallick, G.4    Lin, H.5    Arlinghaus, R.6    Talpaz, M.7
  • 6
    • 31344472945 scopus 로고    scopus 로고
    • Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
    • DOI 10.1016/j.critrevonc.2005.06.007, PII S1040842805001459
    • Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145-164. (Pubitemid 43140744)
    • (2006) Critical Reviews in Oncology/Hematology , vol.57 , Issue.2 , pp. 145-164
    • Walz, C.1    Sattler, M.2
  • 7
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • DOI 10.1126/science.1062538
    • Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
    • (2001) Science , vol.293 , Issue.5531 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Nagesh Rao, P.6    Sawyers, C.L.7
  • 8
    • 0034254368 scopus 로고    scopus 로고
    • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
    • Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96: 1070-1079. (Pubitemid 30616875)
    • (2000) Blood , vol.96 , Issue.3 , pp. 1070-1079
    • Mahon, F.X.1    Deininger, M.W.N.2    Schultheis, B.3    Chabrol, J.4    Reiffers, J.5    Goldman, J.M.6    Melo, J.V.7
  • 11
    • 24344482346 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of imatinib
    • DOI 10.2165/00003088-200544090-00001
    • Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894. (Pubitemid 41252840)
    • (2005) Clinical Pharmacokinetics , vol.44 , Issue.9 , pp. 879-894
    • Peng, B.1    Lloyd, P.2    Schran, H.3
  • 12
    • 0032528339 scopus 로고    scopus 로고
    • Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia
    • Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574-588. (Pubitemid 28323721)
    • (1998) Blood , vol.92 , Issue.2 , pp. 574-588
    • Pallisgaard, N.1    Hokland, P.2    Riishoj, D.C.3    Pedersen, B.4    Jorgensen, P.5
  • 15
    • 0028813711 scopus 로고
    • Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
    • Kantarjian HM, Smith TL, OBrien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122: 254-261.
    • (1995) Ann Intern Med , vol.122 , pp. 254-261
    • Kantarjian, H.M.1    Smith, T.L.2    Obrien, S.3    Beran, M.4    Pierce, S.5    Talpaz, M.6
  • 17
    • 43249083718 scopus 로고    scopus 로고
    • Imatinib pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: A subanalysis of the IRIS study
    • Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028.
    • (2008) Blood , vol.111 , pp. 4022-4028
    • Larson, R.A.1    Druker, B.J.2    Guilhot, F.3
  • 18
    • 57049115901 scopus 로고    scopus 로고
    • Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
    • Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271-275.
    • (2009) Leuk Res , vol.33 , pp. 271-275
    • Forrest, D.L.1    Trainor, S.2    Brinkman, R.R.3
  • 19
    • 67049087117 scopus 로고    scopus 로고
    • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study
    • Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.
    • (2009) Blood , vol.113 , pp. 5401-5411
    • Noens, L.1    Van Lierde, M.A.2    De Bock, R.3
  • 20
    • 67649218742 scopus 로고    scopus 로고
    • Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: A report by the Nagasaki CML Study Group
    • Sakai M, Miyazaki Y, Matsuo E, et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009; 89:319-325.
    • (2009) Int J Hematol , vol.89 , pp. 319-325
    • Sakai, M.1    Miyazaki, Y.2    Matsuo, E.3
  • 21
    • 33846818881 scopus 로고    scopus 로고
    • Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)
    • DOI 10.1016/j.leukres.2006.05.019, PII S0145212606002037
    • Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res 2007;31:574-575. (Pubitemid 46210044)
    • (2007) Leukemia Research , vol.31 , Issue.4 , pp. 574-575
    • Horikoshi, A.1    Takei, K.2    Sawada, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.